Search company, investor...

LunaPBC

lunadna.com

Founded Year

2017

Stage

Unattributed | Alive

Total Raised

$12.4M

Last Raised

$3.8M | 2 yrs ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+10 points in the past 30 days

About LunaPBC

LunaPBC is the creator of LunaDNA, a health and genomic data platform owned by its community of personal health information donors. LunaDNA empowers individuals to share their health data for medical research and the greater good of the community. As community owners in the LunaDNA platform, members share in the value created from health discoveries and medical breakthroughs.

Headquarters Location

10070 Mesa Rim Rd

San Diego, California, 92121,

United States

ESPs containing LunaPBC

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTH ➡MARKET STRENGTH ➡LEADERHIGHFLIEROUTPERFORMERCHALLENGER
Life Sciences / Biopharma Tech

Startups in this market use genetic screening services to identify individuals with hereditary risks for disease, including cancer and heart conditions. As the market for direct-to-consumer genomics wanes — partially due to increased FDA regulation — companies in this space have pivoted to partner with healthcare providers and integrate genomics data into clinical care.

LunaPBC named as Outperformer among 13 other companies, including Color, Congenica, and PierianDx.

Compete with LunaPBC?

Ensure that your company and products are accurately represented on our platform.

LunaPBC's Products & Differentiators

    Service: Organize a Study Cohort

    1) Create new or engage with an existing registry, foundation, community 2) Operate internationally 3) Engage privacy protected and continuously connected participants (even post-study) 4) Work with patients directly, remotely, digitally

Expert Collections containing LunaPBC

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

LunaPBC is included in 4 Expert Collections, including Digital Health 150.

D

Digital Health 150

150 items

2019's cohort of the most promising digital health startups transforming the healthcare industry

G

Game Changers 2018

36 items

Our selected startups are high-momentum companies pioneering technology with the potential to transform society and economies for the better.

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Health

13,069 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

LunaPBC Patents

LunaPBC has filed 10 patents.

The 3 most popular patent topics include:

  • Biological databases
  • Bioinformatics
  • Data management
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/30/2019

9/20/2022

Cryptocurrencies, Data management, Health informatics, Social networking services, Alternative currencies

Grant

Application Date

4/30/2019

Grant Date

9/20/2022

Title

Related Topics

Cryptocurrencies, Data management, Health informatics, Social networking services, Alternative currencies

Status

Grant

Latest LunaPBC News

AGSAA, Biogen, LunaPBC, And Genetic Alliance Launch Community-Led Discovery Program For Aicardi-Goutières Syndrome

Feb 4, 2022

Program incorporates families to inform research and drug development San Diego, CA /PRNewswire/ - The Aicardi-Goutières Syndrome Americas Association (AGSAA) , LunaPBC , and Genetic Alliance today announced a program to assemble a patient-led drug discovery community studying the disease etiology of a rare neurodevelopmental disorder known as Aicardi-Goutières syndrome (AGS) and support development of therapeutic treatments for this devastating disease. The program is being launched in collaboration with Biogen, Inc. and represents Biogen's second collaboration with Luna and Genetic Alliance. The program will engage patients and their families, patient advocates, and pharmaceutical partners to create a patient-driven trial design—with patients and their parents as the stewards of their data with the goal of incorporating the optimal clinical and behavioral features and the most desired trial endpoints in the drug discovery process. Luna's proprietary Community-Driven Innovation technology will align families and researchers on their key priorities and needs. "The passion of these parents drives research on this condition like never before," said Sharon Terry, president and CEO of Genetic Alliance. "Genetic Alliance is so excited to support these families. Our work with Luna is the kind of paradigm shift we saw in lots of other industries. People truly at the center, calling the shots." AGS primarily affects the developing brain and immune system of infants and toddlers, most often resulting in profound developmental delays, lifelong physical impairments, and persistent neurological changes. Most newborns with AGS do not display any signs or symptoms at birth but go on to develop severe brain dysfunction within the first two years of life, often after months of typical development and good health. In AGS, the body's immune system turns on itself in a destructive way, targeting myelin, or white matter, in the brain and significantly impacting the nervous system. Additionally, immune dysfunction associated with AGS can affect many other organs of the body, sometimes in a life-threatening manner. This can include the lungs, the liver, the heart, the skin, blood cells, and the kidneys. Because the signs and symptoms of the disorder are similar to those of a congenital viral infection, AGS is extremely difficult to diagnose. Although rare, increasing awareness of AGS has revealed higher prevalence than previously ascertained. In order to manage severe progression and improve quality of life for affected individuals and their families, both early identification and timely access to emerging treatments are essential interventions. The program gives the AGS community the power to shape clinical studies that have the potential to answer their needs more quickly and efficiently. This framework, constructed from deep dives into AGS's digital world and real-world interviews with parents and patients, helps guide researchers toward the most accurate observations and endpoints that will be built into the study design to increase participant engagement and retention, to ensure interventions meet the goals and needs of patients, to capture real-world and patient-reported insights, and to facilitate comprehensive, longitudinal study. "This partnership represents a key element of our 'human-first' drug discovery approach at Biogen," said Sally John, Head of Translational Biology at Biogen. "We have learned how important it is to engage patients early in the process. The program will provide a deeper understanding of the natural history of the disease and insight into the families' lived experiences to help enable discovery of novel medicines and clinical research that best meet the needs of patients." The framework also enables children and their parents to participate in studies from the comfort and safety of their homes, thereby reducing the hardship on families, increasing participation, and expediting research. "This partnership represents an incredible opportunity to not only document and validate the lived experiences of families grappling with Aicardi-Goutières syndrome, but actually use these hard-won insights to shape the future of research and treatment options" said Devon Cordova, vice president of the AGSAA. "With committed community engagement and thoughtful stewardship of our data, we will finally have what we need to tell our story and begin to write a different ending." To learn more and determine eligibility to participate, visit https://www.agsamericas.org/ags-patient-registry to join and help accelerate discovery. Source: LunaDNA

LunaPBC Frequently Asked Questions (FAQ)

  • When was LunaPBC founded?

    LunaPBC was founded in 2017.

  • Where is LunaPBC's headquarters?

    LunaPBC's headquarters is located at 10070 Mesa Rim Rd, San Diego.

  • What is LunaPBC's latest funding round?

    LunaPBC's latest funding round is Unattributed.

  • How much did LunaPBC raise?

    LunaPBC raised a total of $12.4M.

  • Who are the investors of LunaPBC?

    Investors of LunaPBC include Illumina Ventures, ARCH Venture Partners, Bain Capital Ventures, Osage Venture Partners, F-Prime Capital and 8 more.

  • Who are LunaPBC's competitors?

    Competitors of LunaPBC include PierianDx, Mega Genomics, Human Longevity, Veritas Genetics, Color, Congenica, Platomics, 54gene, Genome Medical, ixLayer and 12 more.

  • What products does LunaPBC offer?

    LunaPBC's products include Service: Organize a Study Cohort and 4 more.

  • Who are LunaPBC's customers?

    Customers of LunaPBC include Biogen, National Society of Genetic Counsellors, PXE International and AliveAndKickn Lynch Syndrome Hereditary Cancer Foundation.

Compare LunaPBC to Competitors

Color Logo
Color

Color democratizes access to genetic information. The Color Test is physician-ordered and comes with complimentary board-certified genetic counseling for clients and healthcare providers. The 30-gene Color Test analyzes genes closely associated with some of the most common hereditary cancers: breast, colorectal, melanoma, ovarian, pancreatic, prostate, stomach, and uterine cancers.

Human Longevity Logo
Human Longevity

Human Longevity is building a comprehensive database of human genotypes and phenotypes as a basis for a variety of commercialization opportunities to help solve aging-related disease and human biological decline. The company is developing and applying large-scale computing and machine learning to make discoveries from this data to generate personalized health insights. Its goal is to extend healthy human life by impacting human health and transforming the practice of medicine. Human Longevity was founded in 2013 and is based in San Diego, California.

54gene Logo
54gene

54gene is an online genetics platform for people of African heritage.

Geneseeq Logo
Geneseeq

Geneseeq is committed to the research and clinical translation of Next-Generation Sequencing (NGS) in the field of personalized medicine. The company has developed a pan-genomic testing system, which can detect the genetic abnormalities of 416 cancer-related genes. The system can be used for the detection of a number of cancers, such as lung cancer, gastro-intestinal cancer, breast cancer and gynecological cancer.

P
PrognomIQ

PrognomIQ is a healthcare company pursuing the development and commercialization of multi-omics human tests for cancer and other complex diseases.

Platomics Logo
Platomics

Platomics is developing a genetic data analysis software called PlatoX and intends to create an online marketplace for laboratories to provide genetic testing.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.